Controlling neuroinflammation in Alzheimers Disease
Grant number: 1044714 | Funding period: 2013 - 2015
Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.
Related publications (3)
Deletion of the type-1 interferon receptor in APP(SWE)/PS1(Delta E9) mice preserves cognitive function and alters glial phenotype
Myles R Minter, Zachery Moore, Moses Zhang, Kate M Brody, Nigel C Jones, Sandy R Shultz, Juliet M Taylor, Peter J Crack
A neuro-inflammatory response is evident in Alzheimer's disease (AD), yet the precise mechanisms by which neuro-inflammation influ..
Ablation of Type-1 IFN Signaling in Hematopoietic Cells Confers Protection Following Traumatic Brain Injury
Ila P Karve, Moses Zhang, Mark Habgood, Tony Frugier, Kate M Brody, Maithili Sashindranath, C Joakim Ek, Stephane Chappaz, Ben T Kile, David Wright, Hong Wang, Leigh Johnston, Maria Daglas, Robert C Ates, Robert L Medcalf, Juliet M Taylor, Peter J Crack
Type-1 interferons (IFNs) are pleiotropic cytokines that signal through the type-1 IFN receptor (IFNAR1). Recent literature has im..